{"entity":{"id":"alcam","kind":"target","name":"ALCAM","aka":["activated leukocyte cell adhesion molecule","CD166 antigen","CD166"],"tldr":"ALCAM (CD166 antigen) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.","summary":"Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6.\n\nCIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Fluorouracil.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:400","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:400"},{"label":"UniProt Q13740","url":"https://www.uniprot.org/uniprotkb/Q13740/entry"},{"label":"NCBI Gene 214","url":"https://www.ncbi.nlm.nih.gov/gene/214"},{"label":"Ensembl ENSG00000170017","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000170017"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"ALCAM","role":["drug-target","biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:400","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:400","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q13740","url":"https://www.uniprot.org/uniprotkb/Q13740/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene ALCAM","url":"https://civicdb.org/features/259","note":"1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0)"}],"distribution":"one-type","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA ALCAM: RNA tissue enriched (parathyroid gland 413 nTPM); blood lineage lineage enriched (dendritic cells 30 nTPM); high antibody staining in 18 normal tissues; highest cancer staining prostate cancer (12 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Colorectal cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas ALCAM tissue","url":"https://www.proteinatlas.org/ENSG00000170017-ALCAM/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000170017 associations","url":"https://platform.opentargets.org/target/ENSG00000170017/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:400","ensembl":"ENSG00000170017","uniprot":"Q13740","entrez":"214","firstDescribed":1995,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Bowen M.A. et al, J. Exp. Med, 1995, \"Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7760007/","biology":"Cell adhesion molecule that mediates both heterotypic cell-cell contacts via its interaction with CD6, as well as homotypic cell-cell contacts. Promotes T-cell activation and proliferation via its interactions with CD6. Contributes to the formation and maturation of the immunological synapse via its interactions with CD6. Mediates homotypic interactions with cells that express ALCAM. Acts as a ligand for the LILRB4 receptor, enhancing LILRB4-mediated inhibition of T cell proliferation. Required for normal haematopoietic stem cell engraftment in the bone marrow. Location: Cell membrane; Cell projection, axon; Cell projection, dendrite; Secreted (UniProt). Locus 3q13.11 (HGNC).","whereFound":["Colorectal cancer: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/alcam/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}]}}